CERAXON - is a nootropic medicine that is used to treat cerebrovascular disorders, head injury and Parkinson's disease. Ceraxon provides a vast range of actions: improves cholinergic transmission and reduces the amount of damaged tissue after acute phase of stroke; reduces the duration of post-traumatic coma and the severity of neurological symptoms after traumatic brain injury; stimulates the formation of new phospholipids, thus improving the function of ion-exchange membrane pumps nerve cells; stabilizes the membrane of neurons; restores damaged cell membranes, inhibits the action of phospholipases by preventing excessive formation of free radicals, and prevents cell death by affecting the mechanisms of apoptosis. Ceraxon is effective in the treatment of cognitive disorders such as memory loss, lack of initiative, the difficulties in carrying out daily activities and self-care. It increases the level of attention and consciousness, as well as reduces amnesia. Ceraxon is effective in treating sensory and motor neurological degenerative disorders and vascular etiology. Read more about Citicoline.
INDICATION FOR USE
INSTRUCTION FOR USE
Active substance: citicoline sodium (equivalent to 500mg citicoline)
Excipients: 1M hydrochloric acid or 1M sodium hydroxide, рH 6,7-7,1, water for injections max-4ml
Ceraxon is administered by slow intravenous injection (duration 3-5 min) or by drip infusion (40-60 drops/min). The intravenous rout is preferred.
Acute phase of stroke and traumatic brain injury: recommended dose is 1000mg every 12 hours, duration - not less than 6 weeks.
Recovery therapy after ischemic and hemorrhagic strokes, traumatic brain injury, cognitive impairment of degenerative and vascular etiology:†recommended dose is 500-2000mg/day (5-10ml 1-2 times per day).
Parkinson's disease: recommended dose is 500mg 1 time per†day for 3-4 weeks.
PRODUCER: Ferrer Internacional, S.A.
NOTE: Please consult your physician prior to using this or any other nutritional supplements or medications.
Please, contact us if you have any questions.